Aptar Pharma Announces Development and License Agreement With BD To Bring A Novel Auto-Injector To Market

Aptar Pharma, a leading drug delivery solutions provider and segment of AptarGroup, Inc. announced the signing of an exclusive development and license agreement with BD (Becton, Dickinson and Company) to jointly develop a novel auto-injector using Aptar Pharma’s high- performance, two-step auto-injector technology and prefillable syringes from BD. Anticipating unmet medical needs for self-injection

This content was submitted directly to this website by the supplier.

Anticipating unmet medical needs for self-injection
Auto-injectors are designed to be used safely and conveniently by patients for self-injection in a non-medical environment, such as the home or office.

Aptar Pharma has utilized feedback obtained from its market research involving patients and healthcare professionals to create and optimize a compact device capable of delivering high viscosity drugs including some of the newest biologics.

A robust system approach
The auto-injector technology was specifically designed around the BD NeopakTM 1mL long glass prefillable syringe or the BD HypakTM for Biotech 1 mL long glass prefillable syringe to optimize system robustness and performance.

A strong collaboration
Under the agreement, BD, a leading global medical technology company with a broad portfolio of innovative drug delivery systems, and Aptar Pharma will jointly develop Aptar Pharma’s auto-injector technology platform using BD’s expertise in prefillable syringes and self-injection technologies combined with Aptar Pharma’s innovation and quality-by-design expertise.


This unique two-step auto-injector will be exclusively commercialized by BD as a part of their portfolio of auto-injectors.


“We are pleased to be extending our relationship with BD from pharmaceutical elastomer components supplier to now also include joint development of an auto-injector system.


The key advantages of this platform hinge on the ease of use, ergonomic shape, improved feedback indicators, and the ability to handle viscous drug formulations,” said Salim Haffar, President of Aptar Pharma.

>>For More information, click here.

More in Home